¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Agents primarily affecting the cardiovascular system"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 4
¿µ¹® central nervous system(CNS) ÇÑ±Û ÁßÃ߽Űæ°è
¼³¸í   
  ½Å°æ°è´Â ÁßÃ߽Űæ°è¿Í ¸»ÃʽŰæ°è·Î ºÐ·ùÇÒ ¼ö°¡ ÀÖ´Ù. ÁßÃ߽Űæ°è¶õ ³ú¿Í Ã´¼ö·Î ±¸¼ºµÇ¾î Àִ ½Å°æ°è¸¦ À̸£´Â ¸»ÀÌ´Ù. ¸»ÃʽŰæ°è¶õ ÀÌ ÀÌ¿ÜÀÇ ¸ðµç ½Å°æ°è¸¦ À̸£´Â ¸»ÀÌ´Ù. 
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • gate control system
    °ü¹®Á¶Á¤ÀåÄ¡
  • general system theory
    ÀϹÝü°è·Ð
  • genital system
    »ý½Ä°èÅë, »ý½Ä°è, »ý½Ä±â°è
  • genitourinary system
    ºñ´¢»ý½Ä°èÅë, ºñ´¢»ý½Ä°è
  • Haversian system
    ÇϹö½º°è
  • health care delivery system
    ÀÇ·áÀü´Þü°è
  • hypophyseal portal system
    ³úÇϼöü¹®¸Æ°è
  • health care system
    º¸°ÇÀÇ·áü°è
  • health information system
    º¸°ÇÁ¤º¸Ã¼°è
  • hematopoietic system
    Ç÷±¸Çü¼º°èÅë, Á¶Ç÷°è
  • hospital information system
    º´¿øÁ¤º¸Ã¼°è
  • immobilization system
    °íÁ¤¹æ½Ä
  • immune system
    ¸é¿ªÃ¼°è
  • impulse conducting system
    ½ÉÀåÈïºÐÀüµµ°èÅë
  • information system
    Á¤º¸Ã¼°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • digestive system
    ¼ÒÈ­°èÅë
  • display system
    Ç¥½ÃÀåÄ¡
  • distric health system
    Áö¿ªº¸°Çü°è
  • drug delivery system
    ¾à¹°Àü´Þü°è
  • dual foil system
    ÀÌÁß¹Ú¸·±¸Á¶
  • dynamic system
    µ¿Àû°èÅë
  • ecological system
    »ýŰè
  • electro transfer system
    ÀüÀÚÀü´Þ°è, ÀüÀÚ¿î¹Ýü
  • electro-optical system
    Àü±â±¤Çкм®°è
  • endocrine system
    ³»ºÐºñ°èÅë
  • exhaust system
    ¹èÃâÀåÄ¡, ¹è±â½Äȸ·Î
  • exteroceptive nervous system
    ¿Ü¼ö¿ë½Å°æ°è
  • family system theory
    °¡Á·Ã¼°è·Ð
  • gas disposal system
    °¡½ºÃ³¸®ÀåÄ¡
  • gate control system
    °ü¹®Á¶Á¤ÀåÄ¡
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Rh blood group system
    Rh Ç÷¾×Çü±º
  • Rh system
    RhÇ÷¾×Çü°è
  • Rosenfield system
    ·ÎÁ¨Çʵå°è
  • SI unit => International System of Unit
    ±¹Á¦±Ô°Ý´ÜÀ§
  • T system
    T°èÅë.
  • V-Tech urinalysis system
    V-Tech ¿äºÐ¼®Ã¼°è
  • Wiener system
    À§³Êü°è
  • Wilkerson point system
    ÀªÄ¿½¼Á¡¼öü°è
  • achromatic system
    ¹«»ö°è.
  • acid-base buffer system
    »ê¿°±â¿ÏÃæ°è
  • adrenal medulla,tumor of chemoreceptor system
    È­Çмö¿ëü°è Á¾¾ç(ûùùÊáôé»ô÷ͧ ðþåË)
  • adrenal system
    ºÎ½Å°è(Üùãìͧ).
  • aerospace life support system
    (Ç×°ø)¿ìÁÖ¿ë »ý¸íÀ¯Áö½Ã½ºÅÛ.
  • affectional system
    Á¤µ¿Ã¼°è
  • alimentary system(tract)
    ¼ÒÈ­±â°è(á¼ûùÐïͧ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • bicarbonate buffer system
    Áßź»ê¿°¿ÏÃæ°è(ñì÷©ß«ç¤èÐõúͧ).
  • biliary system
    ´ã°ü°è(ÓÅηͧ), ´ãµµ°è(ÓÅԳͧ).
  • biliary system
    ´ãµµ°è(ÓÅԳͧ)
  • biliary system
    ´ã°ü°è(´ã°ü°è), ´ãµµ°è(´ãµµ°è).
  • biliary system(tract)
    ´ãµµ°è(ÓÅԳͧ)
  • bioenergetic system
    »ý¹°¿¡³ÊÁö°è.
  • blood group system
    Ç÷¾×Çü±º
  • breathing system
    È£ÈíÀåÄ¡(¡­íûöÇ).
  • buffer system
    ¿ÏÃæ°è
  • capitation system
    ÀεÎÁ¦, ȯÀÚµî·ÏÁ¦.
  • cardiac conducting system
    ½ÉÀåÀüµµ°èÅë
  • cardiac conduction system
    ½ÉÀå ÈïºÐ Àüµµ°è(ãýíôýéÝÇîîÓôͧ)
  • case payment system
    Æ÷°ý¼ö°¡Á¦
  • central nervous system
    ÁßÃ߽Űæ°è(ñéõÒãêÌèͧ)
  • central nervous system
    ÁßÃ߽Űæ°èÅë, ÁßÃ߽Űæ°è(ñéõÒãêÌèͧ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • restriction-modification system
    Á¦ÇÑ ¼ö½Ä(áóãÞ) ½Ã½ºÅÛ
  • reticuloendothelial system
    ¸Á»ó³»ÇÇ(ØÑßÒÒ®ù«) ½Ã½ºÅÛ
  • Rh blood group system
    Rh Ç÷¾×Çü(úìäûúþ) ½Ã½ºÅÛ
  • RS system
    RS ½Ã½ºÅÛ
  • schlieren optical system
    ½¯¸®·» ±¤ÇÐ(ÎÃùÊ)½Ã½ºÅÛ
  • selective system
    ¼±ÅÃ(àÔ÷É) ½Ã½ºÅÛ
  • state of a system
    ½Ã½ºÅÛ »óÅÂ(ßÒ÷¾)
  • system
    ½Ã½ºÅÛ
  • transport system
    ¼ö¼Û(âÃáê)½Ã½ºÅÛ
  • T system
    T ½Ã½ºÅÛ
  • V system
    V ½Ã½ºÅÛ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ACCA American College of Cardiovascular Administrators
ACV acute cardiovascular [disease]; acyclovir; assisted controlled ventilation; atrial/carotid/ventricul...
ASHCVD atherosclerotic hypertensive cardiovascular disease
CC calcaneal-cuboid; calcium cyclamate; cardiac catheterization; cardiac contusion; cardiac cycle; card...
CCI Cardiovascular Credentialing International; cholesterol crystallization inhibitor; chronic coronary ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CVM Cardiovascular malformations
CVR Cardiovascular reactivity
CVRF Cardiovascular risk factor
CATCH Child and Adolescent Trial for Cardiovascular Health
MONICA MONItoring Trends and Determinants in CArdiovascular Disease
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dynamic system
    µ¿Àû °èÅë
  • ectopic system
    »ýŰè
    ¾î¶² Áö¿ªÀÇ »ý¹° °øµ¿Ã¼¿Í À̰ÍÀ» À¯ÁöÇϰí ÀÖ´Â ¹«±âÀû ȯ°æÀÌ Á¾ÇÕµÈ ¹°Áú°è ¶Ç´Â ±â´É°è. »ýŰè¶õ ¿µ±¹ÀÇ A.G. ÅĽ½¸®¿¡ ÀÇÇÏ¿© 1935³â Á¦Ã¢µÈ ¿ë¾î·Î, ÀÚ¿¬ÀÇ ÀÖ´Â ±×´ë·ÎÀÇ »óŸ¦ ÀνÄÇϱâ À§Çؼ­´Â ÀÌ°Íµé »óÈ£°£ÀÇ °ü°è¸¦ Áö´Ñ »ý¹°°ú ¹«±âÀû ȯ°æÀ» Çϳª·Î ÅëÇÕÇØ¾ß ÇÑ´Ù´Â °ÍÀÌ ÅĽ½¸®°¡ Á¦Ã¢ÇÑ °³³äÀÌ´Ù. Áö±¸ »ýŰè´Â ±× ³ÐÀÌ¿¡¼­´Â »ý¹°±Ç°ú ÀÏÄ¡ÇÑ´Ù. ¹«±âÀû ȯ°æÀÇ Æ¯Â¡¿¡ ÀǰÅÇÏ¿© ÇØ¾ç »ýŰè, È£¼Ò »ýŰè, ±ØÁö »ýŰè, »ç¸· »ýÅÂ°è µîÀ¸·Î ±¸º°Çϰí, ¶Ç ±º¶ôÀÇ »ó°ü¿¡ µû¶ó¼­ »ï¸² »ýŰè, ÃÊÁö »ýÅÂ°è µîÀ¸·Î ±¸ºÐÇϱ⵵ ÇÑ´Ù. ¶ÇÇÑ, °æÁö »ýŰè, µµ½Ã »ýŰè¿Í °°Àº °Íµµ »ý°¢ÇÒ ¼ö ÀÖ´Ù. »ýŰè Áß¿¡¼­ »ý¹°Ã¼´Â ±â´ÉÀûÀ¸·Î »ý»êÀÚ
  • endocrine system
    ³»ºÐºñ°è
    ÀÎüÀÇ Á¶Àý ±â´ÉÀ¸·Î ¼¼Æ÷°£ÀÇ ´ëÈ­¸¦ È­ÇÐ ¹°ÁúÀΠȣ¸£¸óÀ» ÅëÇØ¼­ È­ÇÐÀûÀÎ ½ÅÈ£¸¦ ÀÌ¿ëÇÏ¿© Ç¥Àû ¼¼Æ÷µé¿¡ ÀÛ¿ëÇÑ´Ù. ÈçÇÑ ³»ºÐºñ°è ÀÌ»óÀº ºñÁ¤»óÀûÀÎ ¼ºÀå, ¿¡³ÊÁö ¼öÁØ º¯È­ ¿Âµµ º¯È­¿¡ÀÇ ºÎÀûÀÀ ¹× ¼³¸íµÇÁö ¾Ê´Â üÁß º¯È­·Î ³ªÅ¸³­´Ù. ´Ù´¢, °úµµÇÑ °¥Áõ, üÁß °¨¼Ò¸¦ µ¿¹ÝÇÑ ½Ä¿å °ú´Ù´Â ´ç´¢º´ÀÇ Æ¯Â¡ÀÌ´Ù. ½Ã·Â º¯È­, ½ÅÀå ±â´ÉÀå¾Ö, »çÁöÀÇ Ç÷¾× ¼øÈ¯ °¨¼Ò´Â Àå±â°£ÀÇ ´ç´¢·Î ÀÎÇÑ ÁøÇàµÈ Ç÷°ü °æÈ­ÀÇ Áõ»óÀÌ´Ù.
  • endogenous analgesic peptide system
    ³»¿ø¼º ÁøÅ뼺 ÆéƼµå°è
  • epidermal system
    Ç¥Çǰè
  • excretory system
    ¹è¼³°è
  • extrapyrarnidal system
    Ãßü¿Ü·Î°è
  • fiber optic delivery system
    ±¤ ¼¶À¯ Àü´Þ°è
  • fingerprint system
    Áö¹®°è
  • fusimotor system
    ¹æÃß ¿îµ¿°è
  • human system
    ÀÎü°è
  • hypophyseal portal system
    ³úÇϼöü ¹®¸Æ °èÅë, Çϼöü ¹®¸Æ°è
  • hypothalamohypophyseal system
    ½Ã»ó ÇϺΠ³úÇϼöü°è
  • hypothalamopituitary system
    ½Ã»ó ÇϺΠ³úÇϼöü°è
  • hypothalamus pituaitary system
    ½Ã»ó ÇϺΠ³úÇϼöü°è
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
antimanic agents Agents that are used to treat bipolar disorders or mania associated with other affective disorders.
(12 Dec 1998)
antimutagenic agents Agents that reduce the frequency or rate of spontaneous or induced mutations independently of the mechanism involved.
(12 Dec 1998)
antineoplastic and immunosuppressive agents Collective grouping for substances used to arrest the proliferation of malignant cells and those that suppress the immune response.
(12 Dec 1998)
anti-obesity agents Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (niddm) to treat obesity.
(12 Dec 1998)
antiparasitic agents Drugs used to treat or prevent parasitic infections.
(12 Dec 1998)
antiparkinson agents Agents used in the treatment of parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
(12 Dec 1998)
anti-platelet agents Medications that, like aspirin, reduce the tendency of platelets in the blood to clump and clot.
(12 Dec 1998)
antiplatyhelmintic agents Agents used to treat cestode, trematode, or other flatworm infestations in man or animals.
(12 Dec 1998)
antiprotozoal agents Agents destructive to protozoans or that check their growth or reproduction, especially those causing protozoan infections in man and animal.
(12 Dec 1998)
antipsychotic agents Agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in schizophrenia, senile dementia, transient psychosis following surgery or myocardial infarction, etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
(12 Dec 1998)
antipsychotic agents, butyrophenone Those butyrophenone derivatives used in the treatment of psychoses.
(12 Dec 1998)
antipsychotic agents, phenothiazine Phenothiazine derivatives used in the treatment of psychoses.
(12 Dec 1998)
antirheumatic agents Drugs that are used to treat rheumatoid arthritis.
(12 Dec 1998)
antirheumatic agents, gold Gold salts that are effective in the therapy of rheumatoid arthritis. These compounds usually do not have analgesic activity. Since these compounds are poorly absorbed from the intestinal tract, they are usually given intramuscularly.
(12 Dec 1998)
antisickling agents Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • feudal system
    ºÀ°Ç Á¦µµ
  • fixed exchange rate(system)
    °íÁ¤È¯½Ã¼¼(Á¦)
  • floating exchange rate system
    º¯µ¿ ȯÀ²Á¦
  • fractional orbital bombardment system
    ºÎºÐ ±Ëµµ Æø°Ý üÁ¦
  • freeflying system
    ÀÚÀ¯ ºñÇà ½Ã½ºÅÛ
  • haversian system
    ÇϹö½º°è(ÇϹö½º°ü°ú À̸¦ µÑ·¯ ½Ñ °ñÁ¶Á÷ ³»ÀÇ ±¸¼º ´ÜÀ§)
  • honor system
    ¹«°¨µ¶ ½ÃÇèÁ¦µµ;(Çü¹«¼ÒÀÇ)¹«°¨½Ã Á¦µµ
  • hot water system
    ½ºÆÀ¿ë ¹è°ü
  • hydraulic system
    À¯¾Ð ÀåÄ¡(°èÅë)(À¯¾ÐÀ¸·Î Á¶Á¾°èÅëÀ̳ª Âø·úÀåÄ¡¸¦ ÀÛµ¿½ÃŰ´Â
  • incompatible color(system)
    tv ºñ¾ç¸³½Ä(º¸Åë Èæ¹é ¼¼Æ®¿¡´Â ¼ö»óµÇÁö ¾Ê´Â Ä÷¯ ÅÚ·¹ºñÀü¹æ½Ä)
  • inertia navigation system
    °ü¼º Ç×¹ý ½Ã½ºÅÛ
  • information system
    Á¤º¸½Ã½ºÅÛ(ƯÈ÷)µ¥ÀÌŸó¸® ½Ã½ºÅÛ
  • instrument landing system
    (°ø)°è±âÂø·úÀåÄ¡(¹æ½Ä)
  • integrated system
    (ÀüÀÚ)ÁýÀû½Ã½ºÅÛ(ÁýÀûȸ·ÎÀü¹ÝÀ» °¡¸®Å´)
  • intercommunication system
    (¹è,ºñÇà±â,ÀüÂ÷µîÀÇ)³»ºÎÅëÈ­(ÀåÄ¡)ÀÎÅÍÄÞ;ÀÎÅÍÆù
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á